We have located links that may give you full text access.
Comparative Study
Evaluation Study
Journal Article
Video-assisted mediastinoscopic lymphadenectomy combined with minimally invasive pulmonary resection for left-sided lung cancer: feasibility and clinical impacts on surgical outcomes†.
European Journal of Cardio-thoracic Surgery 2016 January
OBJECTIVES: Although video-assisted mediastinoscopic lymphadenectomy (VAMLA) has greatly increased the accuracy of mediastinal staging, its clinical value as a therapeutic tool for complete mediastinal lymph node dissection in the treatment of left-sided lung cancer is not well elucidated.
METHODS: We identified the consecutive 649 patients with left-sided lung cancer undergoing minimally invasive pulmonary resection between July 2002 and June 2013. Among them, 225 patients underwent VAMLA combined with pulmonary resection (VAMLA + VATS group), while the remaining 424 patients underwent VATS procedure only (VATS group). Operative outcomes including procedural time, removed lymph nodes and node stations, complications and the final pathological mediastinal staging in the both groups were evaluated and compared.
RESULTS: There was no significant difference in the baseline profiles between the two groups. The patients in the VATS + VAMLA group showed significantly shorter operative time (116.8 ± 39.8 vs 159.8 ± 44 .0 min; P < 0.001), more extensive lymph node dissection (total number of removed lymph nodes, 29.7 ± 10.8 vs 23.0 ± 8.6; P < 0.001) and the higher rates of patients with mediastinal lymph nodes removed: Station 2 on the right (12.4 vs 0.2%), Station 2 on the left (15.1 vs 0.2%), Station 4 on the right (42.7 vs 0.9%), Station 4 on the left (87.6 vs 57.3%) and Station 7 (100 vs 99.3%), while maintaining comparable surgical morbidities compared with the VATS group. Also, the patients in the VATS + VAMLA group tended to have higher rates of being upstaged with mediastinal involvement (8.0 vs 5.7%; P = 0.31).
CONCLUSIONS: VAMLA is a clinically feasible procedure safely performed as a therapeutic tool for complete mediastinal lymph node dissection (MLND), and can be a good complement to minimally invasive pulmonary resection in left-sided lung cancer, where optimal MLND is not always feasible with VATS approach. Further studies are required to investigate the long-term clinical impacts of VAMLA with regard to survival and tumour recurrence.
METHODS: We identified the consecutive 649 patients with left-sided lung cancer undergoing minimally invasive pulmonary resection between July 2002 and June 2013. Among them, 225 patients underwent VAMLA combined with pulmonary resection (VAMLA + VATS group), while the remaining 424 patients underwent VATS procedure only (VATS group). Operative outcomes including procedural time, removed lymph nodes and node stations, complications and the final pathological mediastinal staging in the both groups were evaluated and compared.
RESULTS: There was no significant difference in the baseline profiles between the two groups. The patients in the VATS + VAMLA group showed significantly shorter operative time (116.8 ± 39.8 vs 159.8 ± 44 .0 min; P < 0.001), more extensive lymph node dissection (total number of removed lymph nodes, 29.7 ± 10.8 vs 23.0 ± 8.6; P < 0.001) and the higher rates of patients with mediastinal lymph nodes removed: Station 2 on the right (12.4 vs 0.2%), Station 2 on the left (15.1 vs 0.2%), Station 4 on the right (42.7 vs 0.9%), Station 4 on the left (87.6 vs 57.3%) and Station 7 (100 vs 99.3%), while maintaining comparable surgical morbidities compared with the VATS group. Also, the patients in the VATS + VAMLA group tended to have higher rates of being upstaged with mediastinal involvement (8.0 vs 5.7%; P = 0.31).
CONCLUSIONS: VAMLA is a clinically feasible procedure safely performed as a therapeutic tool for complete mediastinal lymph node dissection (MLND), and can be a good complement to minimally invasive pulmonary resection in left-sided lung cancer, where optimal MLND is not always feasible with VATS approach. Further studies are required to investigate the long-term clinical impacts of VAMLA with regard to survival and tumour recurrence.
Full text links
Related Resources
Trending Papers
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app